XerisDD (@XerisDD) header
XerisDD (@XerisDD) profile picture

A Community of Due Diligence on Xeris BioPharma ($XERS).

Chicago, IL
Joined June 2021
Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)Photo by XerisDD (@XerisDD)
$XERS Baqsimi reviews on WebMD not getting any better. Eventually the #diabetes community will be well aware of the painful side effects of Baqsimi. #Baqsimi Reviews - 2.4 of 5 stars #Gvoke Reviews - 5.0 of 5 stars
4
6
1
36
10,052
XerisDD retweeted
$XERS raises 2030 total revenue outlook to more than $1B, up from approximately $750M. What is most impressive about this is that there is still NO revenue assumption for 8121.
8
4
37
4,053
$XERS Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Raises full-year 2026 total revenue guidance to $395 million to $405 million Raises 2030 total revenue outlook to more than $1 billion,
1
1
2
16
2,011
Bump $xers
When does the Lundbeck offer leak? $XERS
10
753
XerisDD retweeted
There is speculation that $XERS could be in play now as a takeover after a rejected bid. I think it is extremely unlikely that a deal will come soon, as there will be too much of a discount for Levo at this point. The TAM there is well over a billion and it becomes more concrete as the studies progress. The good news is that the interest will put a floor under the stock as we await data.
4
2
25
3,733
XerisDD retweeted
$XERS XERIS Biopharma price target raised to $14 from $12 at Barclays Barclays analyst Jenna Davidner raised the firm's price target on Xeris Biopharma to $14 from $12 and keeps an Overweight rating on the shares. The firm sees a strong setup for the company into the Q3 report with its pipeline "gaining traction." Barclays remains confident in the trajectory for Recorlev and XP-8121 and thinks Xeris' valuation "remains undemanding."
1
16
2,903
When does the Lundbeck offer leak? $XERS
4
1
17
2,459
XerisDD retweeted
Replying to @RevShark
At $6.7B market cap, Lundebeck is too small to pull this off. Peak estimates of $2 - 3B for Recorlev and Levo put $XERS at a $6 - 9B valuation, $33 - 49 per share. Maybe another Danish pharma will make an offer $NVO
1
1
13
1,099
No. $XERS management knows they need to advance LEVO further before they can maximize a buyout
2
9
779
XerisDD retweeted
Long since 11/4/22. People/investors are soooo funny....a takeover doesn't materialize in 24 hrs so they bail on a bio that has 3 approved drugs amd quite possibly a 4th on the way. $xers
2
1
8
614
XerisDD retweeted
this is insane. i genuinely don't understand why ambitious people aren't shown this lecture before their careers start consuming their entire lives. clayton christensen spent his career studying why successful companies collapse. in his final class, he asked students to apply the theory to themselves: if you keep allocating your time the same way, what life are you actually building? he had already seen the answer in his own harvard mba class. everyone looked successful at the fifth reunion; by the 10th, 15th, 20th, and 25th, many were unhappy, divorced, and living far from their children. work shows you the score immediately. close a sale, ship a product, finish a presentation, earn a promotion, get paid. an hour with your child may produce nothing you can measure today; it may take 20 years to understand what that hour built. so the next free hour goes back to work, one rational decision at a time. this is how people build lives they never planned: through hundreds of right decisions that lead in the wrong direction, day after day. money, titles, and headcount are easy to count. christensen believed a life should be measured by the people who became better because you were there. he died in 2020. one question remains: if someone saw only where your time, energy, and attention went this year, what would they think actually mattered to you? the full 19-minute lecture is in the video below.
161
4,644
265
28,385
3,910,118
XerisDD retweeted
$XERS XP-8121 now has a hard date. The Sept 9 webinar is the catalyst that starts the analyst re-rating. Management will "review the Phase 3 development program… details of the pivotal Phase 3 study… comprehensive clinical development plan… and discuss the commercial opportunity," with a KOL. This will force the Street to build launch numbers into estimates.
2
2
29
4,386
XerisDD retweeted
Hey @jimcramer thanks for jumping in on $XERS I knew it was only a matter of time 😂
Hey @jimcramer I hope you grabbed some $XERS when you mentioned them on your show a couple of weeks ago. This train is not stopping!
1
1
1
7
1,515
$XERS at close ...
1
1
476
XerisDD retweeted
Hey @jimcramer I told you about $XERS last week. Now you missed out on 8.5% gain over last 5 days. Not too late.
Replying to @jimcramer
Now’s the time to pick up some $XERS that you mentioned on your show this week.
1
1
6
1,824
$XERS trying to push through the 200-day SMA
2
2
10
2,879
One thing I like about this $XERS transaction is that Morgan Stanley ($MS) is the bank involved. Nice to have a top investment bank dealing with this little stock
3
2
23
3,637
$XERS I'll write up the details later on @thestreetpro about the $XERS deal. It is an interesting study in corporate financing. They are paying to reduce interest expense and are removing some future dilution. I like that they have the financial strength to do something like this.
$XERS. This looks like a nice move to improve eps. Xeris Biopharma announces private exchange of convertible notes Xeris Biopharma entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028. Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to retire approximately $23M aggregate principal amount of the Notes for exchange consideration consisting of approximately $23M in cash and a number of shares of its common stock that will be determined based upon the volume-weighted average price per share of Xeris' common stock over a 21 trading day averaging period commencing on June 11. Assuming the per share volume-weighted average price of Xeris' common stock during each day of the averaging period is $6.71, Xeris expects to issue an aggregate of approximately 4.6M shares of common stock upon consummation of the exchanges. Following the closing of the exchanges, Xeris will have $10.5M in aggregate principal amount of the Notes outstanding. Morgan Stanley acted as placement agent to the Company in connection with the exchanges.
1
3
19
4,432
XerisDD retweeted
Replying to @RevShark
Interesting XERS was mentioned by a caller last night. Cramer had an interesting response TymeTryethTroth 8:56 AM $XERS - Jim Cramer “I recognize this one because I happen to be involved in some stuff related to it that I don’t talk about but…(proceeds to briefly recommend it)
1
1
1
275